 for the proper dosing regimen in order to maximize the visual benefits for their patients. In conclusion, our ongoing clinical development programs for dupilumab, EYLEA, Kevzara, Praluent, and our immuno-oncology portfolio show promising progress in various indications. Our upcoming top line data and new initiations in clinical studies will continue to drive our efforts to bring important advances to patients in need. Thank you for your attention, and we look forward to keeping you updated on our progress.